



Equity in Genomics

A Brief Report on Cardiovascular Health Disparities in African American Adults

Jewel Scott, PhD, MSN, FNP-C; Lakeshia Cousin, PhD, APRN; Jennifer Woo, PhD, CNM/WHNP, FACNM; Rosa Gonzalez-Guarda, PhD, MPH, RN, CPH, FAAN; Leigh Ann Simmons, PhD, MFT

Background: African Americans are more likely to die from cardiovascular disease (CVD) than all other populations in the United States. Although technological advances have supported rapid growth in applying genetics/genomics to address CVD, most research has been conducted among European Americans. The lack of African American representation in genomic samples has limited progress in equitably applying precision medicine tools, which will widen CVD disparities if not remedied. **Purpose:** This report summarizes the genetic/genomic advances that inform precision health and the implications for cardiovascular disparities in African American adults. We provide nurse scientists recommendations for becoming leaders in developing precision health tools that promote population health equity. **Conclusions:** Genomics will continue to drive advances in CVD prevention and management, and equitable progress is imperative. Nursing should leverage the public's trust and its widespread presence in clinical and community settings to prevent the worsening of CVD disparities among African Americans.

KEY WORDS: African American, cardiovascular health, genomics, health disparities, race and ethnicity

Cardiovascular disease (CVD) is the leading cause of death in the United States, and African American adults are disproportionately affected.¹ The overall prevalence of hypertension in the United States is 29%, but the prevalence is 44% in African American women and 42% in African American men, respectively.¹ Mortality rates from sudden cardiac death in black men are twice that of their white counterparts (175 vs 84 per 100 000, respectively).¹ Furthermore, the black-white racial gap in CVD mortality, including sudden cardiac death, hypertension, and ischemic heart disease, is estimated to be responsible for more than 5 million years of life lost between 1999 and 2010.² Although the sentinel report “Unequal Treatment” moved racial and ethnic health disparities to the forefront of the nation's clinical, research,

and policy agendas, pervasive disparities persist in the cardiovascular (CV) health of people of African descent living in the United States.^{1,2}

Although genomics/genetics have the potential to improve the prevention and management of CVD, the bulk of this research has occurred in people of European descent. Since completion of the mapping of the human genome in 2003, researchers have applied genetics/genomics knowledge to CVD prevention by identifying how changes in the genome or the expression of the genome may attenuate or increase CV risk.^{3–6} Increasingly, genetics and genomics are being used to anticipate response to medications (eg, antihypertensives and anticoagulants)^{7,8} and to explore how behaviors and social experiences interact with biological factors to influence

Jewel Scott, PhD, MSN, FNP-C

Doctoral Trainee, Duke University School of Nursing, Durham, North Carolina.

Lakeshia Cousin, PhD, APRN

Postdoctoral Fellow, Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.

Jennifer Woo, PhD, CNM/WHNP, FACNM

Assistant Professor, Texas Women's University, Dallas.

Rosa Gonzalez-Guarda, PhD, MPH, RN, CPH, FAAN

Associate Professor, Duke University School of Nursing, Durham, North Carolina.

Leigh Ann Simmons, PhD, MFT

Professor and Chair, Department of Human Ecology, University of California, Davis.

J.S. is funded in part by the Robert Wood Johnson Foundation Future of Nursing Scholars program and the National Institute of Nursing Research, grant #1F31-NR018579-01. The views expressed here do not necessarily reflect the views of the funding organizations.

The authors have no conflicts of interest to disclose.

Correspondence

Jewel Scott, PhD, MSN, FNP-C, Duke University School of Nursing, DUMC Box 3322, 307 Trent Dr, Durham, NC 27710 (Jewel.Scott@duke.edu).

DOI: 10.1097/JCN.0000000000000725

health.^{9–12} The rapid advancements in genomics research have been one of several areas of precision medicine or personalized health, which consider differences in people's genes, environments, and lifestyles to develop treatment and prevention strategies based on the unique constellation of these factors in different individuals. However, because most genetics and genomics research has been conducted in homogenous groups of European descent, much of this knowledge is not applicable to African Americans. Consequently, the “promise” of precision health cannot be realized universally and may in fact perpetuate already critical health inequities in CV health for African Americans.

In this report, we present a concise, narrative description of genetic/genomic advances that are informing precision health and the implications for addressing CV disparities in African Americans. We provide an important contextual background by reviewing the pertinent history, accomplishments, and challenges in CV genetics/genomics on reducing CV health disparities in African Americans. We also present examples of how results of genomic analyses may differ by ancestry and the research opportunities that could have an impact on reducing inequities and informing future nursing practice.

“Race” in Genetics

Genetics/genomics in CVD disparities must be understood within the social construct of race. Despite having no biological basis, hierarchical categories based on skin color have been used to define “race,”^{13,14} and historically, the construct of race has been used to understand population differences in health outcomes. Thus, there are concerns that genetics/genomics research may be misunderstood as legitimizing race, may risk the idea of “genetic determinism,” and/or may exacerbate stereotypes of people of color. Science demonstrates, however, that between any 2 humans, there is more shared genomic material than different genetic material,¹³ yet small differences in the genome can have significant implications for health and wellness. Population stratification, or the presence of systematic differences in the genome due to ancestry, is a common reason for differences in the genome.⁸ Ancestry refers to the geographical origin of one's ancestors and is an entirely different concept than the social construct of race.^{13,14}

Genomics and Cardiovascular Health Inequities: Past

A historical perspective provides context for how inequities in CVD and genomics research have emerged and enhances understanding of why representation of individuals from different ancestries in genomics research is equally important to social justice and scientific advancement. A brief recounting of CV discovery for the last 2 decades provides concrete examples of how advances

in genomics may inadvertently exacerbate CV health inequities. In the mid-2000s, genome-wide association studies (GWASs) using innovative technology that rapidly scanned entire genomes accelerated the pace of genetic/genomic discovery for complex diseases such as CVD.^{5,6} In 2007, the first genome risk variants associated with coronary artery disease were identified on the chromosome 9p21 region by 2 independent teams of investigators, both using research samples of European ancestry.^{3,4} The risk variants are associated with increased atherosclerotic burden in individuals of European ancestry but are not associated with atherosclerosis in people of African ancestry.^{15,16} In 2014, Ni and Zhang¹⁷ hypothesized that the reduced frequency of the risk allele in people of African descent has not been established, because it would require larger sample sizes than currently available to detect a potential relationship. The association with CVD could be a type 2 error, because of inadequate representation of racial and ethnic diversity in genomics research, or conversely, could be due to population stratification.

Research on the genetic architecture of coronary artery disease suggests that changes in a nucleotide base pair, called a single-nucleotide polymorphism, that are associated with CVD are population specific. Genetic variants at any single locus may have different effects on disease outcomes based on ancestry. With the significant disparity in hypertension prevalence in African Americans and the cadre of diseases associated with blood pressure, significant research has focused on unraveling the genetics of blood pressure. One of the first GWASs in a sample of African Americans aimed to replicate the findings from the first ever GWAS of blood pressure completed in 2007.¹⁸ Investigators tested the 6 polymorphisms that were closest to statistical significance in the original study in a multiethnic sample of 11 000 US residents.¹⁸ Of the 6 polymorphisms tested, only one, rs1937506, was significantly associated with blood pressure. However, the effect of the single base pair switch differed in 3 ethnic groups. In individuals of European descent, this change resulted in an almost 25-mm Hg decrease in blood pressure. In individuals of Hispanic heritage, the same change elevated blood pressure by almost 25 mm Hg. There was no effect on blood pressure in participants of African ancestry.¹⁸ Similar findings were reported from a recent meta-analysis of subclinical CVD from 8 studies, with a total sample size of 5800 African Americans.¹⁹ None of the 67 polymorphisms previously shown to be associated with outcomes in people of European descent met genome-wide significance for coronary artery calcium (calcified plaque). Furthermore, 2 of the 3 polymorphisms (in *SOX9* and *PRKCA*) trended toward significance, but with the opposite effect of what was seen in a European American sample.¹⁹ The authors noted that small effects could possibly be detected in a larger sample; however, at the time, they had already

included every available data point for coronary artery calcium. These studies clearly demonstrate how the lack of diversity in existing genomics samples may impede progress in risk identification, tailored interventions, and pharmaceutical therapies, all of which are components of current and future precision health.

Genomics and Health Inequities: Misconceptions

Cardiovascular diseases are complex, with factors such as health behaviors, social influences, and genetic risk all contributing individually and cumulatively. Genetic variation is one of many factors that contribute to multifactorial diseases such as CVD. Thus, changes in the genome are not deterministic, but rather, gene expression is modified by the environment, health behaviors, and other biological factors. For example, the adverse social experience of discrimination can interact with genetic risk variants to raise blood pressure through various pathways such as reducing typical nighttime reductions in blood pressure.^{9,10} Tobacco use is a health behavior that raises CVD risk and may interact with genetic risk variants. In a sample of almost 1100 African American women, Taylor and colleagues¹¹ identified 2 polymorphisms on chromosomes 14 and 17 that did not have a direct effect on blood pressure but interacted with cigarette use to raise systolic blood pressure. Likewise, lifestyle factors such as physical activity can attenuate harm from genetic risk.¹² Integrating multifactorial contributors to CV health is important to (1) understand how

CVD inequities have unfolded, (2) determine future research needs, and (3) establish best practices for applying genomics/genetics information to prevention and treatment strategies in the context of other social influences on health.

Genomics and Health Inequities: Representation Matters

The geographic representation in genomics research has increased since 2007, but representation from people of African and Latin American ancestry lags.^{8,20} In 2009, the proportion of people in GWASs of European descent was 96%. Although that percentage is now approximately 80%, much of the increase in diversity is due to the increased inclusion of Asian populations, up to 11% (Figure), with participants of African ancestry making up less than 3% of GWASs.⁸ Because of poor representation, African Americans are more likely to be given false results from genetic tests²⁰ or to not benefit from genomics-enhanced risk assessment and prescribing algorithms.⁸ As such, they do not receive the highest quality or technologically advanced care available, and this exacerbates already established disparities in CVD outcomes.

Genomics and Cardiovascular Health Disparities: Nursing Implications

Distributive Justice

Advocating for equitable access to the benefits of advances in genomics research is a principle of distributive justice.²¹




FIGURE. Racial and ethnic diversity of individuals in the NHGRI GWAS catalog. N = 110 291 046, ancestry labels listed as provided by the GWAS catalog. Abbreviations: GWAS, genome-wide association study; NHGRI, National Human Genome Research Institute. Data available at <https://www.ebi.ac.uk/gwas/ancestry> (last accessed September 28, 2019).

One way that nursing can contribute to distributive justice is through patient education. As a community-facing profession, nursing can leverage the nation's established trust in nurses to engage African American participants in genomics/genetics research, including providing information about the risks, benefits, capabilities, and limitations of genetics/genomics research. Studies show that racial and ethnic minority populations are concerned about the health of their communities and are more willing to participate in genetic studies when they are well informed, preferably in close collaboration with the research team.²² Successful participation of minoritized populations, such as African Americans, in genetics research requires multiple methods of recruitment that are thoughtful, intentional, and tailored.²³ Taylor, a nurse scientist, used innovative recruitment methods using historically black sororities, participant resource pools, and churches to successfully recruit 42 African American generational triads (grandmothers, mothers, and granddaughters) into a hypertension genetics study.²³ The challenges of recruiting underrepresented minorities into genetics/genomics research must be overcome, because ultimately, oversampling of these population subgroups will be needed to move toward distributive justice.²¹

In 2018, the leadership committee of the American Heart Association Council on CV and Stroke Nursing identified precision CV nursing care as a priority area for future research.²⁴ The council's leaders encouraged nurse researchers to incorporate genomics and epigenomic measures into their research as a way to personalize interventions for disease prevention and healthcare delivery for different populations. More research is needed to examine how genetic variation interacts with health behaviors, and the social and physical environment to contribute to susceptibility to CVD. In addition, nurse researchers can investigate innovative, ethical approaches for recruiting and consenting African American individuals and other minoritized ethnic groups in the United States into genomics studies. The mistrust of racial and ethnic minority communities toward researchers stems from a history of structural and governmental practices that have disregarded the best interest and autonomy of the individual.²⁵⁻²⁷ A recent study of African American nurses discussing challenges related to seeking and using genomics information identified opt-out consent forms, which assume consent unless participants actively decline, as a potential trust degrading practice.²⁵ Other research suggests that racial and ethnic minorities prefer opt-in consent,²⁶ although this is not a consistent finding.²⁷ Although opt-out may yield more participants, there may be longer term ethical costs and repercussions. There is an opportunity for nurse ethicists and researchers to investigate best practices for consenting African American adults for CV health studies involving genomics and the potential to develop innovative trust-building practices.

Nursing Informatics

Embracing communication technology is another strategy that nursing can use to promote genomic health equity. Clinical nurses can partner with nurse informaticians to design tools for the electronic health record to promote timely and equitable translation of genomics knowledge into practice. Recent policy recommendations from the American Academy of Nursing advocate for improving the health information technology infrastructure to advance equitable precision health implementation.^{28,29} One suggestion is to include a 3-generation family history in the electronic record, which could be used to identify individuals who may be at risk for a genetically linked disease.²⁸ For example, long QT syndrome is an example of an inherited cardiac disease responsible for sudden cardiac death, and it has a genetic cause in at least 75% of individuals.³⁰ Having nurses who are trained to conduct a thorough, comprehensive family history²⁸ and implementing clinical decision support to trigger when a referral is indicated could identify patients at risk who might otherwise be missed.

Incorporating nurse navigators who assist with care coordination of genetic counseling referrals, respond to patients' concerns and misconceptions about genetics testing, facilitate discussions about genomics and precision health clinical trials, and identify potential barriers related to mistrust is an important area of future CV research.³¹ Nursing leaders participating in a recent roundtable on genomics and precision health identified that using nurse navigators has successfully addressed some health disparities in oncology.²⁹ Once patients receive a genetic counseling referral, having culturally sensitive nurse navigators who can assist in brokering the process from referral generated to appointment completed could yield similar successes for CVD. Nurse researchers should investigate clinical outcomes, best practices, and cost-effectiveness of such interventions, as well as training-specific needs for precision health nurse navigators. Nurse scientists and colleagues with a doctorate in nursing practice could partner together on many of these research initiatives such as study design, implementation in the clinical setting, and translation of key findings into nursing practice.

Telehealth

Telenursing has been used to extend care to communities that may be missed, such as rural locations, and as communications technology advances, it can be leveraged to advance equitable dissemination of genomic-based healthcare. Advanced practice nurses are already providing genetic evaluation and counseling using telehealth technology.³² Although this technology has been most widely used in oncology and obstetric care, there are potential applications for CV healthcare. Registered and advanced practice nurses could use telehealth technology to provide genetics-informed guidance on titration

What's New and Important?

- Genetic advancements are changing how CV conditions are diagnosed and managed in nursing practice.
- The geographic representation in genomics research has increased since 2007, but representation from people of African ancestry lags. The lack of ancestral diversity in CV genomics increases the risk of worsening health inequities.
- Nurse scientists can advocate for the equitable inclusion of African Americans in genomics research, prioritize research that incorporates genomic and epigenetic measures to better understand CVH disparities, and collaborate with clinician leaders to promote equitable translation of genomics knowledge into practice.

of medications (eg, warfarin), health education, and initiation of antihypertensive treatment. Removing barriers to care by bringing genomics-based healthcare to patients in the community could help level the playing field.

Telehealth has been accelerated to the forefront of primary and specialty care with COVID-19, and whereas the infrastructure and pay systems need further refining, telehealth is likely to become a permanent feature in healthcare. Nursing researchers can prioritize intervention research that leverages telehealth to bring genomics-informed CV care, health education, and medication management into reach for African Americans who may have limited healthcare access. To achieve this goal, the negative effects of structural racism on healthcare and health outcomes will need to be investigated in this context. Critical areas for research will be identifying and addressing manifestations of implicit bias in video and phone appointments, as well as establishing strategies for increasing patient trust in a provider they have not previously met in person.

Genomics and Cardiovascular Health Disparities: Looking Ahead

Some efforts at improving representation of diversity in genetic research are underway. Recognizing the need for larger sample sizes to detect significant associations, both private and public research consortia have formed to pool data from multiethnic research studies to propel CV genomics research forward. The All of Us research program was launched as part of the Precision Medicine Initiative and aims to enroll a million participants who are representative of the broad ancestral backgrounds of people living in the United States. Enrollment commenced in May 2018, and as of July 2019, 175 000 individuals had been enrolled, with more than 75% coming from historically underrepresented communities.³³ Nurse scientists are also increasing the representation of diverse ancestries in genetics/genomics research. In the Intergenerational Impact of Genetic and Psychological Factors on Blood Pressure study, researchers are exploring the

transgenerational transmission of changes in genome expression related to environmental experiences and patterns of behavior through study designs focused on African American families versus only individuals.³⁴ The 2011 National Human Genome Research Institute strategic plan included a broad focus on increasing the diversity in research cohorts, workforce, and education in community settings, and the pending release of the next National Human Genome Research Institute strategic plan in 2020 will hopefully continue this focus. With so many rapid advances in technologies, such as next-generation sequencing, it is an exciting, albeit precarious, time in genomics science, as precision health goals are becoming reality for many, but not all.

The profession of nursing is uniquely positioned to be influential in incorporating genomics and genetics due to nursing's presence across the care continuum. Nurses have earned the most respected profession year after year,³⁵ because we are the ones who sit with patients and decipher complex diagnoses, clinical data, and test results into digestible chunks of information. To maintain that trust and earned respect and to continue to lead as researchers, practitioners, and educators in the genomic era, nurse researchers will need to invest in studying how nursing can integrate genomics into its research profile and be empowered to lead innovative application of precision health tools to improve CVD disparities among African Americans. In addition, nurses have the responsibility to ensure that other healthcare leaders know they have this expertise so that it is appropriately leveraged within their institutions. Nurses are key in translating discoveries from genomics research into improvements in human and population health. Disseminating results to multiple stakeholders, including research participants and the communities they represent, is critical to ensuring that research data are used ethically and equitably and promote trust and transparency in the genomics/genetics research enterprise.

REFERENCES

1. Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. *Circulation*. 2017;136(21):e393–e423.
2. Howard G, Peace F, Howard VJ. The contributions of selected diseases to disparities in death rates and years of life lost for racial/ethnic minorities in the United States, 1999–2010. *Prev Chronic Dis*. 2014;11:E129.
3. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. *Science*. 2007;316(5830):1488–1491.
4. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science*. 2007;316(5830):1491–1493.
5. Roberts R, Stewart AFR. 9p21 and the genetic revolution for coronary artery disease. *Clin Chem*. 2012;58(1):104–112.
6. Visscher PM, Wray NR, Zhang Q, et al. 10 years of GWAS discovery: biology, function, and translation. *Am J Hum Genet*. 2017;101(1):5–22.

7. Gong Y, Wang Z, Beitelshes AL, et al. Pharmacogenomic genome-wide meta-analysis of blood pressure response to β -blockers in hypertensive African Americans. *Hypertension*. 2016;67(3):556–563.
8. Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. *Cell*. 2019;177(1):26–31.
9. Gregoski MJ, Buxbaum SG, Kapuku G, et al. Interactive influences of ethnicity, endothelin-1 gene, and everyday discrimination upon nocturnal ambulatory blood pressure. *Ann Behav Med*. 2013;45(3):377–386.
10. Quinlan J, Pearson LN, Clukay CJ, et al. Genetic loci and novel discrimination measures associated with blood pressure variation in African Americans living in Tallahassee. *PLoS One*. 2016;11(12):e0167700.
11. Taylor JY, Schwander K, Kardia SLR, et al. A genome-wide study of blood pressure in African Americans accounting for gene-smoking interaction. *Sci Rep*. 2016;6:18812.
12. Khera AV, Emdin CA, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. *N Engl J Med*. 2016;375(24):2349–2358.
13. Rotimi C, Shriner D, Adeyemo A. Genome science and health disparities: a growing success story? *Genome Med*. 2013;5(7):61.
14. Yudell M, Roberts D, DeSalle R, Tishkoff S. Taking race out of human genetics. *Science*. 2016;351(6273):564–565.
15. Zhang L, Buzkova P, Wassel CL, et al. Lack of associations of ten candidate coronary heart disease risk genetic variants and subclinical atherosclerosis in four US populations: the Population Architecture using Genomics and Epidemiology (PAGE) study. *Atherosclerosis*. 2013;228(2):390–399.
16. Vargas JD, Manichaikul A, Wang X-Q, et al. Common genetic variants and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2016;245:230–236.
17. Ni X, Zhang J. Association between 9p21 genomic markers and ischemic stroke risk: evidence based on 21 studies. *PLoS One*. 2014;9(3):e90255.
18. Ehret GB, Morrison AC, O'Connor AA, et al. Replication of the Wellcome Trust genome-wide association study of essential hypertension: the Family Blood Pressure Program. *Eur J Human Genet*. 2008;16(12):1507–1511.
19. Wojczynski MK, Li M, Bielak LF, et al. Genetics of coronary artery calcification among African Americans, a meta-analysis. *BMC Med Genet*. 2013;14:75.
20. Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature*. 2016;538(7624):161–164.
21. Cohn EG, Henderson GE, Appelbaum PS. Distributive justice, diversity, and inclusion in precision medicine: what will success look like? *Genet Med*. 2017;19(2):157–159.
22. Jones L, Wells K, Lin HJ, et al. Community partnership in precision medicine: themes from a community engagement conference. *Ethn Dis*. 2018;28(suppl 2):503–510.
23. Taylor JY. Recruitment of three generations of African American women into genetics research. *J Transcult Nurs*. 2009;20(2):219–226.
24. Piano MR, Artinian NT, DeVon HA, Pressler ST, Hickey KT, Chyun DA. Cardiovascular nursing science priorities: a statement from the American Heart Association Council on Cardiovascular and Stroke Nursing. *J Cardiovasc Nurs*. 2018;33(4):e11.
25. Coleman B, Powell-Young YM, Martinez B, Wooters J. Exploration of African-American Nurses' perceptions toward seeking and utilizing genetic information. *J Natl Black Nurses Assoc*. 2018;29(2):9–16.
26. Kaufman D, Bollinger J, Dvoskin R, Scott J. Preferences for opt-in and opt-out enrollment and consent models in Biobank research: a national survey of Veterans Administration patients. *Genet Med*. 2012;14:787–794.
27. Kerath SM, Klein G, Kern M, et al. Beliefs and attitudes towards participating in genetic research—a population based cross-sectional study. *BMC Public Health*. 2013;13(1):114.
28. Starkweather AR, Coleman B, Barcelona de Mendoza V, et al. Strengthen federal and local policies to advance precision health implementation and nurses' impact on healthcare quality and safety. *Nurs Outlook*. 2018;66(4):401–406.
29. Williams JK, Bonham VL, Wicklund C, Coleman B, Taylor JY, Cashion AK. Advocacy and actions to address disparities in access to genomic health care: a report on a National Academies workshop. *Nurs Outlook*. 2019;67(5):605–612.
30. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Europace*. 2011;13(8):1077–1109.
31. Wells KJ, Valverde P, Ustjanauskas AE, Calhoun EA, Risendal BC. What are patient navigators doing, for whom, and where? A national survey evaluating the types of services provided by patient navigators. *Patient Educ Couns*. 2018;101(2):285–294.
32. Lea DH. Expanding nurses' roles in telemedicine & genetics services. *MCN Am J Matern Child Nurs*. 2006;31(3):185–189.
33. Denny JC, Rutter JL, Goldstein DB, et al. The “All of Us” research program. *N Engl J Med*. 2019;381(7):668–676.
34. Taylor JY, Wright ML, Crusto CA, Sun YV. The Intergenerational Impact of Genetic and Psychological Factors on Blood Pressure (InterGEN) study: design and methods for complex DNA analysis. *Biol Res Nurs*. 2016;18(5):521–530.
35. Branam M. Nurses again outpace other professions for honesty, ethics. <https://news.gallup.com/poll/245597/nurses-again-outpace-professions-honesty-ethics.aspx>. Accessed January 5, 2019.